Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors
Journal of Labelled Compounds and Radiopharmaceuticals · 2026
DOI: 10.1002/jlcr.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2026. Verfasst von Narges Aryanpour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Technetium, Radiopharmaceuticals. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Pharmaceutical Science Research Center, School of Pharmacy, Shahid Beheshti University of Medical Sciences.
Abstract (Originalsprache)
The use of medicinal plants as anti‐cancer agents has attracted the attention of researchers. A method is needed for screening the anti‐cancer effects on HER‐2 receptors. In this study, a simple method based on radioligand binding studies was developed for primary screening of medicinal plants on HER‐2 receptors in vitro. Trastuzumab was conjugated to HYNIC in a chemical reaction using NHS‐HYNIC. HYNIC‐Trastuzumab was radiolabeled with [99mTc] using SnCl 2 as a reducing agent and tricine as a coligand. Biological activities of [99mTc]Tc‐HYNIC‐Trastuzumab were determined in saturation binding studies using the SKBR3 cell line. The IC 50 of Mentha pulegium was determined in competition with [99mTc]Tc‐HYNIC‐Trastuzumab on the SKBR3 cell line. Radiochemical purity was ≥ 90% ± 2.08%. Based on the results, radiolabeled Trastuzumab maintained its biological activity after labeling (immunoreactivity = 83%, K d = 7.049 ± 1.861 nM). The IC 50 of Mentha pulegium was 31.3 ± 1.3 μg/mL. [99mTc]Tc‐HYNIC‐Trastuzumab can be used as a radioligand in competition binding studies for primary screening of medicinal plants, peptides, and small molecules in vitro on HER‐2 receptors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Toxicology and Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Förderung
- Pharmaceutical Science Research Center
- School of Pharmacy, Shahid Beheshti University of Medical Sciences
Zitieren
APA
Aryanpour, N., Farnam, G., Shirazi, F. H., & Shahhosseini, S. (2026). Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.70006
Vancouver
Aryanpour N, Farnam G, Shirazi FH, Shahhosseini S. Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors. Journal of Labelled Compounds and Radiopharmaceuticals. 2026. doi:10.1002/jlcr.70006
BibTeX
@article{Aryanpour2026,
author = {Aryanpour, Narges and Farnam, Golrokh and Shirazi, Farshad H and Shahhosseini, Soraya},
title = {Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
doi = {10.1002/jlcr.70006}
}
EUVIMED